[1]Otto G. Liver Transplantation: An Appraisal of the Present Situation. Dig Dis. 2013;31(1):164-169.
[2]Lu TF, Hua XW, Cui XL, et al. Liver transplantation for hepatocellular carcinoma: recent advances in China. J Dig Dis. 2014;15(2):51-53.
[3]Schoening WN, Buescher N, Rademacher S, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013;13(9): 2384-2394.
[4]时军,丁利民.肝移植后肺部感染的因素分析及防治[J].中华普通外科学文献,2010,4(5):34-36.
[5]易永祥,胡亮,韩建波,等.肝移植术后感染情况及预防措施[J].中国老年学杂志,2013,7(33):3084-3085.
[6]陈规划.移植肝脏病学[M].北京:人民卫生出版社, 2010:553.
[7]Roman A, Manito N, Campistol JM, et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev. 2014; 28(2):84-91.
[8]Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010;70(8):965-981.
[9]Hoppe L, Marroni CA, Bressane R, et al. Impact of cytomegalovirus infection on long-term survival after orthotopic liver transplantation. Transplant Proc. 2006;38(6): 1924-1925.
[10]郭丽丽,许红梅.人巨细胞病毒感染的流行病学研究进展[J]. 国际检验医学杂志,2010,31(10):1131-1133.
[11]谷东风,邹和群.器官移植巨细胞病毒感染的流行病学及其诊断新进展[J].中国中西医结合肾病杂志,2012,13(10):926-928.
[12]Razonable RR. Cytomegalovirus infection after liver transplantation: Current concepts and challenges. World J Gastroenterol. 2008;14(31):4849-4860.
[13]Weigand K, Schnitzler P, Schmidt J, et al. Cytomegalovirus Infection After Liver Transplantation Incidence,Risks, and Benefits of Prophylaxis. Transplant Proc. 2010;42(7): 2634-2641.
[14]Tryphonopoulos P, Weppler D, Morris MI, et al. The Effect of Donor-Recipient Cytomegalovirus Serology on Adult Liver Transplantation: A Single Center Experience. Transplantation. 2011;92(9): 1051-1057.
[15]Yamanouchi K, Eguchi S, Takatsuki M, et al. Management of cytomegalovirus infection after living donor liver transplantation. Hepatogastroenterology. 2012;59(113): 231-234.
[16]de Rooij BJ, van der Beek MT, van Hoek B, et al. Mannose-binding lectin and Ficolin-2 gene Polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol. 2011;55(4):800-880.
[17]白纪民,李浩,张晓明,等.肾移植术后巨细胞病毒感染的危险因素分析和血清甘露聚糖结合凝集素的预测价值[J].器官移植,2013, 4(2):79-83.
[18]Allice T, Enrietto M, Pittaluga F, et al. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants:comparison with end-point PCR and pp65 antigen test. J Med Virol. 2006;78(7):915-922.
[19]Ji W, Kim DS, Jung SW, et al. Pre-emptive Therapy for the Cytomegalovirus Infection After Liver Transplantation in Endemic Areas and Its Optimal Diagnostic Method. Transplant Proc. 2013;45(8):3065-3068.
[20]Chen XY, Hou PF, Bi J. et al. Detection of human cytomegalovirus DNA in various blood components after liver transplantation. Brazil J Med Biol Res. 2014;47(4):340-344.
[21]Bosch W, Heckman MG, Pungpapong S, et al. Association of Cytomegalovirus Infection and Disease With Recurrent Hepatitis C After Liver Transplantation. Transplantation. 2012;93(7):723-728.
[22]Linares L, Sanclemente G, Cervera C, et al. Influence of Cytomegalovirus Disease in Outcome of Solid Organ Transplant Patients. Transplant Proc. 2011;43(6):2145-2148.
[23]San-Juan R, De Dios B, Garcia-Reyne A, et al. Limited impact of cytomegalovirus infection in the long-term outcome of renal and liver transplant. J Clin Virol. 2013;56(4):316-322.
[24]Wang GS, Chen GH, Lu MQ, et al. Original article Immunomodulatory therapy of cytomegalovirus pneumonia after liver transplantation. Chin Med J. 2006;119(17): 1430-1434.
[25]Milan A, Sampaio AM, Guardia AC, et al. Identification of bacterial infections and clinical manifestation associated with cytomegalovirus in liver transplantation patients. Transplant Proc. 2013;45(3):1130-1132.
[26]Togashi J, Sugawara Y, Hashimoto M, et al. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: A randomized trial. BioScience Trends. 2011; 5(5):217-222.
[27]Fisher RA, Kistler KD, Ulsh P, et al. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation. Transpl Infect Dis. 2012;14(2):121-131.
[28]Rollag H, Asberg A, Ueland T, et al. Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: Markers of Inflammation as Predictors of Outcome. Transplantation. 2012;94(10):1060-1065.
[29]Muller V, Perrakis A, Meyer J, et al. The Value of Pre-emptive Therapy for Cytomegalovirus after Liver Transplantation. Transpl Proc. 2012;44(5):1357-1361.
[30]Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008;8(1):158.
[31]Katsolis JG, Bosch W, Heckman MG, et al. Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients. Transpl Infect Dis. 2013;15(2):171-180.
[32]Bodro M, Sabe N, Liado L, et al. Prophylaxis Versus Preemptive Therapy for Cytomegalovirus Disease in High-Risk Liver Transplant Recipients. Liver Transpl. 2012; 18(9):1093-1099.
[33]Kim SI, Kim CJ, Kim YJ, et al. Antiviral Prophylaxis Versus Preemptive Therapy to Prevent Cytomegalovirus Infection and Related Death in Liver Transplantation: A Retrospective Study With Propensity Score Matching. Transpl Proc. 2012; 44(3):787-790.
[34]Lautenschlager I, Loginov R,Makisalo H, et al. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients. J Clin Virol. 2013;57(1):50-53.
[35]Davoudi S, Kasraianfard A, Ahmadinejad Z, et al. Cytomegalovirus reactivation and preemptive therapy after liver transplant. Exp Clin Transplant. 2014;12(1):72-75.
[36]Razonable RR. Cytomegalovirus infection after liver Transplantation:Current concepts and challenges. World J Gastroenterol. 2008;14(31):4849-4860.
[37]Harvala H, Stewart C, Muller K, et al. High Risk of Cytomegalovirus Infection Following Solid Organ Transplantation Despite Prophylactic Therapy. J Med Virol. 2013;85(5):893-898.
[38]Onor IO, Todd SB, Meredith E, et al. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int. 2013;26(6): 592-600.
[39]Metselaar,HJ, van Campenhout MJ, van der Eijk AA. The best way to prevent cytomegalovirus infection after liver transplantation: the debate goes on. Transpl Int. 2013;26(6): 590-591.
[40]Andrassy J, Hoffmann VS, Rentsch M, et al. Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor-Based Immunosuppression? A Systematic Review and Meta-Analysis. Transplantation. 2012; 94(12):1208-1217. |